持续葡萄糖监测与常规治疗对接受每日多次胰岛素注射的1型糖尿病成人血糖控制的影响:GOLD随机临床试验
在瑞典15家糖尿病门诊开展的开放标签交叉随机临床试验,纳入161例接受每日多次胰岛素注射且HbA1c≥7.5%的1型糖尿病成人,比较持续葡萄糖监测与常规治疗各26周(间隔17周洗脱期)的HbA1c差异。持续葡萄糖监测期间平均HbA1c为7.92%,常规治疗期间为8.35%,平均差异-0.43%(95%CI -0.57%至-0.29%,P<.001),支持持续葡萄糖监测。
要点
- 持续葡萄糖监测26周较常规治疗降低HbA1c,平均差异-0.43%(95%CI -0.57%至-0.29%)。
- 常规治疗组5例、持续葡萄糖监测组1例发生严重低血糖;洗脱期使用常规治疗时7例发生严重低血糖。
- 19个次要终点中6个达到统计学显著性,支持持续葡萄糖监测。
核心结论
- 在血糖控制不佳、接受每日多次胰岛素注射的1型糖尿病成人中,与常规治疗相比,使用持续葡萄糖监测26周可降低HbA1c。
- 原文指出需进一步研究评估临床结局和长期不良事件。
研究设计与样本
- 开放标签交叉随机临床试验,2014年2月24日至2016年6月1日在瑞典15家糖尿病门诊开展。
- 纳入161例1型糖尿病成人,HbA1c至少7.5%(58 mmol/mol),接受每日多次胰岛素注射。
- 受试者随机接受持续葡萄糖监测系统或常规治疗26周,两治疗期间间隔17周洗脱期。
主要发现
- 161例随机受试者平均年龄43.7岁,45.3%为女性,平均HbA1c为8.6%(70 mmol/mol)。
- 142例在兩個治疗期均有随访数据。
- 持续葡萄糖监测期间平均HbA1c为7.92%(63 mmol/mol),常规治疗期间为8.35%(68 mmol/mol),平均差异-0.43%(95%CI -0.57%至-0.29%)或-4.7(-6.3至-3.1 mmol/mol),P<.001。
- 19个次要终点(包括心理社会和多种血糖指标)中6个达到统计学显著性的分层检验标准,支持持续葡萄糖监测优于常规治疗。
- 常规治疗组5例和持续葡萄糖监测组1例发生严重低血糖;洗脱期患者使用常规治疗时7例发生严重低血糖。
局限性
- 原文指出需进一步研究评估临床结局和长期不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The majority of individuals with type 1 diabetes do not meet recommended glycemic targets. OBJECTIVE: To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily insulin injections. DESIGN, SETTING, AND PARTICIPANTS: Open-label crossover randomized clinical trial conducted in 15 diabetes outpatient clinics in Sweden between February 24, 2014, and June 1, 2016 that included 161 individuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) treated with multiple daily insulin injections. INTERVENTIONS: Participants were randomized to receive treatment using a continuous glucose monitoring system or conventional treatment for 26 weeks, separated by a washout period of 17 weeks. MAIN OUTCOMES AND MEASURES: Difference in HbA1c between weeks 26 and 69 for the 2 treatments. Adverse events including severe hypoglycemia were also studied. RESULTS: Among 161 randomized participants, mean age was 43.7 years, 45.3% were women, and mean HbA1c was 8.6% (70 mmol/mol). A total of 142 participants had follow-up data in both treatment periods. Mean HbA1c was 7.92% (63 mmol/mol) during continuous glucose monitoring use and 8.35% (68 mmol/mol) during conventional treatment (mean difference, -0.43% [95% CI, -0.57% to -0.29%] or -4.7 [-6.3 to -3.1 mmol/mol]; P < .001). Of 19 secondary end points comprising psychosocial and various glycemic measures, 6 met the hierarchical testing criteria of statistical significance, favoring continuous glucose monitoring compared with conventional treatment. Five patients in the conventional treatment group and 1 patient in the continuous glucose monitoring group had severe hypoglycemia. During washout when patients used conventional therapy, 7 patients had severe hypoglycemia. CONCLUSIONS AND RELEVANCE: Among patients with inadequately controlled type 1 diabetes treated with multiple daily insulin injections, the use of continuous glucose monitoring compared with conventional treatment for 26 weeks resulted in lower HbA1c. Further research is needed to assess clinical outcomes and longer-term adverse effects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02092051.
引用
- Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017. PMID: 28118454. doi:10.1001/jama.2016.19976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。